STOCK TITAN

[SCHEDULE 13G] Vir Biotechnology, Inc. Passive Investment Disclosure (>5%)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Vir Biotechnology Inc ownership filing: Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares of Vir Biotechnology common stock, representing 5.79% of the class. The filing shows sole dispositive power over 9,257,235 shares and sole voting power for 41,658 shares. Vanguard states these holdings reflect positions managed by Vanguard Portfolio Management LLC and affiliated business divisions, including securities held by Vanguard funds and certain client accounts. The filing is signed by a Vanguard official.

Positive

  • None.

Negative

  • None.

Insights

Large passive stake reported by Vanguard, typical Schedule 13G disclosure.

Vanguard Portfolio Management reports beneficial ownership of 9,257,235 shares, equal to 5.79% of Vir Biotechnology’s common stock. The filing lists dispositive and limited voting power consistent with index/managed-fund holdings.

Such 13G filings typically indicate passive, investment-company holdings rather than activist intent; subsequent changes would appear in amended filings if Vanguard’s role or percentage shifts.






92764N102

(CUSIP Number)
03/31/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Portfolio Management LLC and the following affiliates of Vanguard Portfolio Management LLC or business divisions of such affiliates: Vanguard Fiduciary Trust Company and Vanguard Global Advisers, LLC. This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Portfolio Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power. This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Portfolio Management LLC, or business divisions of such subsidiaries whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release.


SCHEDULE 13G



Vanguard Portfolio Management
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:04/29/2026